|Articles|February 1, 2010

Contemporary Pediatrics, Digital Edition, February 2010

Parental vaccine refusal : Helping patients separate fact from fiction Puzzler : Hypotonic baby with failure to thrive Dermcase : Leathery skin, impaired hearing Supporting kids when a parent has cancer

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe

Related Content

FDA approves leniolisib for children aged 4 to 11 years with APDS

ByMorgan Ebert, Executive Editor

September 14th 2026

Tezepelumab meets co-primary and secondary endpoints in phase 3 eosinophilic esophagitis trial

ByMorgan Ebert, Executive Editor

September 14th 2026

FDA approves apitegromab-mstn as first muscle-targeted therapy for spinal muscular atrophy

ByMorgan Ebert, Executive Editor

September 14th 2026

FDA approves leniolisib for children aged 4 to 11 with APDS

ByBenjamin P. Saylor

September 11th 2026

FAQ: What's new in COVID-19, RSV, and flu guidance?

ByContemporary Pediatrics Staff

September 11th 2026

Latest CME

Video

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD

Contemporary Pediatrics, Digital Edition, February 2010

Related Content

FDA approves leniolisib for children aged 4 to 11 years with APDS

Tezepelumab meets co-primary and secondary endpoints in phase 3 eosinophilic esophagitis trial

FDA approves apitegromab-mstn as first muscle-targeted therapy for spinal muscular atrophy

FDA approves leniolisib for children aged 4 to 11 with APDS

FAQ: What's new in COVID-19, RSV, and flu guidance?

Latest CME

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Trending on Contemporary Pediatrics

FAQ: What's new in COVID-19, RSV, and flu guidance?

FDA approves leniolisib for children aged 4 to 11 with APDS

XOCOVA offers new post-exposure COVID-19 prevention option for adolescents

FDA approves apitegromab-mstn as first muscle-targeted therapy for spinal muscular atrophy

Contemporary Pediatrics week in review: September 7-11, 2026